drugset / Trial / NCT07328100

Efficacy and Safety of Coenzyme I for Injection on Vascular Aging.

NCT07328100

Not yet recruiting 60 enrolled Shanghai 10th People's Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Emerging evidence identifies vascular aging independently predicting cardiovascular events, yet effective clinical interventions remain lacking. Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor whose levels decline with age, and preclinical studies suggest that boosting NAD+ can improve vascular function and structure. Preliminary clinical studies in healthy older adults indicate that supplementation with NAD+ precursors, such as nicotinamide riboside(NR) or nicotinamide mononucleotide (NMN), can reduce arterial stiffness as measured by pulse wave velocity (PWV). However, whether NAD+ supplementation can improve vascular endothelial function and exert anti-stiffening effects in patients who have already developed measurable arterial stiffness remains unknown. Based on this evidence, the investigator hypothesize that the Coenzyme I for Injection will reverse vascular aging in older adults with established arterial stiffening.

Timeline

Start
2026-01-16
Primary completion
2027-06-30
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Coenzyme I Unknown Intravenous

Indications